Tilray (NASDAQ:TLRY) Stock Price Down 1.2%

Tilray Inc (NASDAQ:TLRY) was down 1.2% on Monday . The stock traded as low as $1.70 and last traded at $1.70. Approximately 7,325,389 shares were traded during trading, a decline of 71% from the average daily volume of 24,960,863 shares. The stock had previously closed at $1.72.

Tilray Trading Down 0.9 %

The company has a quick ratio of 1.42, a current ratio of 2.27 and a debt-to-equity ratio of 0.10. The stock has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $1.88. The firm has a market capitalization of $1.32 billion, a P/E ratio of -3.86 and a beta of 2.13.

Tilray (NASDAQ:TLRY) last issued its quarterly earnings results on Monday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). Tilray had a negative return on equity of 2.63% and a negative net margin of 30.26%. The business had revenue of $229.90 million for the quarter, compared to analyst estimates of $226.20 million. During the same period in the previous year, the company posted ($0.15) earnings per share. The business’s revenue for the quarter was up 24.8% on a year-over-year basis. As a group, research analysts forecast that Tilray Inc will post -0.16 EPS for the current year.

Hedge Funds Weigh In On Tilray

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLRY. RPO LLC acquired a new position in shares of Tilray during the fourth quarter worth $28,000. Wellington Wealth Strategies LLC. purchased a new position in Tilray during the fourth quarter worth about $29,000. HBK Sorce Advisory LLC purchased a new position in Tilray during the first quarter worth about $37,000. Prospect Financial Services LLC purchased a new position in Tilray during the second quarter worth about $26,000. Finally, Signature Estate & Investment Advisors LLC purchased a new position in Tilray during the second quarter worth about $29,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.